Growth hormone therapy in the glucocorticosteroid-dependent child: Metabolic and linear growth effects

被引:31
作者
Mauras, N [1 ]
机构
[1] Nemours Childrens Clin, Div Endocrinol, Jacksonville, FL 32207 USA
关键词
growth hormone; glucocorticosteroids; growth; insulin-like growth factor-1; inflammatory bowel disease; Crohn's disease; protein metabolism; bone metabolism; body composition; carbohydrate metabolism;
D O I
10.1159/000048128
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pharmacological doses of glucocorticosteroids given chronically are associated with a variety of negative side effects which impact the prolonged use of these potent anti-inflammatory agents. They have catabolic effects on protein, resulting in poor tissue healing, an increased incidence of infections and accelerated bone loss. Insulin resistance to both hepatic and peripheral tissues is a common consequence of chronic steroid use, leading at times to impaired carbohydrate metabolism. Steroids affect both the release and the effects of growth hormone (GH) at the target sites, hence becoming functional GH antagonists. When administered to growing children the side effects of glucocorticosteroid treatment are further compounded by a potent and significant suppression of linear growth. Ample experimental and clinical data support a role for GH therapy in counteracting some of the effects of glucocorticosteroids. Using isotope dilution methods we have previously shown that both GH and insulin-like growth factor (IGF)-I can decrease the protein wasting effects of prednisone administration in man. IGF-I has also been shown to enhance type I collagen formation in hydrocortisone-treated human osteoblasts. GH (through IGF-I) significantly enhances linear growth; thus, in states of 'functional' GH deficiency, such as that observed in chronic steroid use, GH may also have a potentially beneficial effect. Studies in children on chronic prednisone doses with cystic fibrosis, chronic renal failure or juvenile rheumatoid arthritis have all shown beneficial effects on linear growth after prolonged GH therapy. Data from a recent study of ours using GH in children with steroid-dependent inflammatory bowel disease showed that GH treatment was associated with increased lean body mass, decreased adiposity and increased linear growth. Marked increases in IGF-I concentrations and in kinetic measures of bone calcium accretion (using calcium tracers) were also observed, without any deterioration of disease activity scores or carbohydrate tolerance. In conclusion, GH therapy may play a role in the treatment of children on chronic steroids both as a growth promoting agent and as an anabolic agent on whole body protein and bone. Longer term studies will be needed to better define the safety and efficacy of this approach. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 27 条
[11]   Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH- and IGF-I-receptor in cultured rat chondrocytes [J].
Jux, C ;
Leiber, K ;
Hügel, U ;
Blum, W ;
Ohlsson, C ;
Klaus, G ;
Mehls, O .
ENDOCRINOLOGY, 1998, 139 (07) :3296-3305
[12]   INHIBITION BY PREDNISONE OF GROWTH-HORMONE (GH) RESPONSE TO GH-RELEASING HORMONE IN NORMAL MEN [J].
KAUFMANN, S ;
JONES, KL ;
WEHRENBERG, WB ;
CULLER, FL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (06) :1258-1261
[13]   Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis [J].
Lai, HC ;
FitzSimmons, SC ;
Allen, DB ;
Kosorok, MR ;
Rosenstein, BJ ;
Campbell, PW ;
Farrell, PM .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (12) :851-859
[14]   BONE LOSS IN RESPONSE TO LONG-TERM GLUCOCORTICOID THERAPY [J].
LOCASCIO, V ;
BONUCCI, E ;
IMBIMBO, B ;
BALLANTI, P ;
ADAMI, S ;
MILANI, S ;
TARTAROTTI, D ;
DELLAROCCA, C .
BONE AND MINERAL, 1990, 8 (01) :39-51
[16]  
MAURAS N, 2002, METABOLISM, P51
[17]   EFFECTS OF DEXAMETHASONE ON GROWTH-HORMONE (GH)-RELEASING HORMONE, ARGININE AND DOPAMINERGIC STIMULATED GH SECRETION, AND TOTAL PLASMA INSULIN-LIKE GROWTH FACTOR-I CONCENTRATIONS IN NORMAL-MALE VOLUNTEERS [J].
MIELL, JP ;
CORDER, R ;
PRALONG, FP ;
GAILLARD, RC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (03) :675-681
[18]   Growth hormone increases cortical and cancellous bone mass in young growing rats with glucocorticoid-induced osteopenia [J].
Ortoft, G ;
Andreassen, TT ;
Oxlund, H .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (05) :710-721
[19]   THE COURSE OF BIOCHEMICAL PARAMETERS OF BONE TURNOVER DURING TREATMENT WITH CORTICOSTEROIDS [J].
PRUMMEL, MF ;
WIERSINGA, WM ;
LIPS, P ;
SANDERS, GTB ;
SAUERWEIN, HP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (02) :382-386
[20]   CORTISOL-INDUCED INSULIN RESISTANCE IN MAN - IMPAIRED SUPPRESSION OF GLUCOSE-PRODUCTION AND STIMULATION OF GLUCOSE-UTILIZATION DUE TO A POSTRECEPTOR DEFECT OF INSULIN ACTION [J].
RIZZA, RA ;
MANDARINO, LJ ;
GERICH, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1982, 54 (01) :131-138